What's Happening?
Hackensack Meridian John Theurer Cancer Center (JTCC) is set to present 65 studies at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando from December 6-9, 2025. This marks one of JTCC's
most significant contributions to the ASH, showcasing advancements in cell therapy, targeted agents, AI-driven diagnostics, and stem cell transplantation across various hematologic diseases. Dr. André Goy, chair and vice president of oncology at Hackensack Meridian Health, emphasized the center's role in advancing blood cancer care through innovative research and clinical trials. The studies cover a wide range of topics, including leukemia, lymphoma, myeloma, and non-cancerous blood disorders, highlighting JTCC's commitment to bringing transformative science to clinical practice.
Why It's Important?
The research presented by JTCC at the ASH meeting underscores the center's leadership in hematologic oncology and its commitment to improving patient outcomes through innovative treatments. The studies have the potential to influence clinical practices and offer new hope for patients with blood cancers and other serious blood disorders. By focusing on cutting-edge therapies such as CAR-T cell therapy and AI-enabled diagnostics, JTCC is contributing to the evolution of personalized medicine in oncology. This could lead to more effective and targeted treatment options, ultimately improving survival rates and quality of life for patients.
